Primer on Drug Development
Partners in Progress: Cancer Patient Advocates and FDA
November 13, 2017

Gideon Blumenthal, MD
Acting Deputy Director OHOP
Associate Director, Precision Oncology
OHOP/OCE
Outline of this talk

• Cancer drug and diagnostic development at 30,000 feet
• Intro to FDA Oncology
• The drug development process
• The drug approval process and expedited programs
Drug and device development from 30,000 feet

• **Expensive**: estimated $0.6B to $2.7B to develop a drug
• **Takes Time**: estimated average of a decade to go from first in human to FDA approval
• **Risky**: <10% of drugs entering trials are eventually approved
• One of most **complicated human endeavors**! More steps than the lunar landing
• **Increasing complexity**: gene therapy, massively parallel genetic sequencing, immunotherapy
**Systemic Cancer Therapy Timeline**

<table>
<thead>
<tr>
<th>1880s</th>
<th>1940s</th>
<th>1960s</th>
<th>1970s</th>
<th>1980s</th>
<th>1990s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormonal Therapy</td>
<td>Single agent Cytotoxic</td>
<td>Combination Cytotoxic</td>
<td>Adjuvant Therapy</td>
<td>Anti-Emetics</td>
<td>Targeted Therapy</td>
</tr>
<tr>
<td>Oophorectomy and Breast Cancer (Beatson)</td>
<td>(1942) Nitrogen Mustard for Lymphoma</td>
<td>(1948) Farber antifolates and Pediatric ALL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**21st Century**
- Genomics and Personalized Oncology
- Pathways
- Immunotherapy
- Gene Therapy
- Molecular Imaging
Oncology by the numbers

- ~1.7M cases/year in US
- ~595k deaths/year in US
- ~40% of new drug approvals
- ~97% of new companion diagnostic approvals
- > 2000 Immunooncology agents in development
- 34% growth in clinical trials since 2008
Outline of this talk

• Cancer drug and diagnostic development at 30,000 feet
• Intro to FDA Oncology
• The drug development process
• The drug approval process
Key FDA Centers in Oncology Drug Development

Center for Drug Evaluation and Research (CDER)
• Drugs and Antibodies

Center for Biologics Evaluation and Research (CBER)
• Cellular and Gene Therapies, Vaccines

Center for Devices and Radiologic Health (CDRH)
• Devices, In Vitro Diagnostics, Diagnostic and Therapeutic Radiologics
Oncology Center of Excellence / Office of Hematology and Oncology Products

Oncology Products 1
- Breast cancer
- Gynecologic cancers
- Genitourinary cancers
- Supportive care

Oncology Products 2
- Lung, head and neck cancers
- Gastrointestinal cancers
- Melanoma and sarcoma
- Pediatric cancer, neuro-oncology and rare cancers

Hematology Products
- Benign hematology
- Hematologic cancers
- Hematologic support

Hematology and Oncology Toxicology
Pharmacologists / toxicologists supporting each clinical division
Multi-disciplinary Teams

Chemists
Pharmacologists
Toxicologists

Clinical

Project Managers

Statisticians

Keep Calm & Trust Your Project Manager
Striking the Balance

Flexible, Efficient, Interactive

“Too Cautious!
Stifling Innovation!
Reduce regulatory burden!”

“ Toxic deaths!
Delayed safety findings!
FDA asleep at the Wheel”

CERTAINTY
DATA
Regulatory BURDEN

Consistent, Thorough, Independent
Traditional Drug Development

Pre-clinical animal studies → IND Submission / Phase 1 → Phase 2 → Phase 3 → FDA Approv

End of Phase 1 meeting → End of Phase 2 meeting → NDA/BLA review → ODAC meeting

Longer term animal studies

New Indications

3 to 6 years → 6-7 years → 0.5 – 1 year

Food effect/ hepatic/renal impairment/ Drug interactions/ dedicated QT

Post-marketing Requirements
Drug Development paradigm in era of breakthrough therapies

- **Preclinical animal studies**
- **IND Submission / Phase 1**
- **End of Phase 1 meeting**
- **Phase 2**
- **NDA/BLA review**
- **ODAC meeting**
- **FDA Approval**
- **Phase 3**

Food effect/ hepatic/renal impairment/ Drug interactions/ dedicated QT

Post-marketing Requirements

New Indications

- **Longer term animal studies**

- **3 to 6 years**
- **2-4 years**
- **0.5 – 1 year**
Outline of this talk

• Cancer drug and diagnostic development at 30,000 feet
• Intro to FDA Oncology
• The drug development process
• The drug approval process
“Phase I” studies

• Goal: Is the drug safe in humans?
  – Identify dose-limiting toxicities (DLTs)
  – Identify the recommended phase 2 dose (RP2D)

• Dose
  – Single-arm, small numbers of patients
  – Traditionally 3+3 design, or Bayesian adaptive design
“Phase II” studies

• Goal:
  – Initial assessment of clinical activity alone or in combination
  – Further define safety
  – Test/validate biomarkers to identify patients more/less likely to respond

• Design:
  – Frequently: single-arm trial measuring response rate
“Phase III” Studies

• Goal: confirm that the drug is effective

• Design:
  – Usually randomized
  – Ideally “double blind” and compared to placebo
  – In oncology: often not blinded and compared to standard available therapy or added to standard therapy
Recent trends in oncology clinical trials

- Increased reliance on single arm trials, expansion cohorts in phase 1 for breakthrough, transformative therapies
- Increased use of biomarker tests to better predict who will benefit
- Reevaluation of eligibility criteria to improve access and generalizability
  - Organ dysfunction
  - Minimum age
  - Brain metastases
  - Co-infection with HIV
- Increased patient engagement in design, conduct and interpretation of clinical trials
- Utilization of “Real World Evidence” to generate evidence on a drug’s safety and effectiveness
Outline of this talk

• Cancer drug and diagnostic development at 30,000 feet
• Intro to FDA Oncology
• The drug development process
• The drug approval process and expedited programs
New Drug Application (NDA) or Biologics License Application (BLA)

“Sponsor” wants FDA to approve a drug for marketing in the U.S. for use in a specific patient population.

Process:
• Sponsor submits patient-level data to FDA
• Analysis/Discussion of benefits vs. risks by FDA
• If needed: outside opinion through ODAC (Oncologic Drugs Advisory Committee)
• Negotiate Labeling, post-marketing studies
• Regulatory decision
Benefit vs. Risk

Overall Survival: will I live longer?
Progression Free Survival: will it take longer for my cancer to get worse?
Response Rate: will my cancer shrink?

Mild symptoms
Moderate symptoms
Severe symptoms
Life-threatening symptoms
Death
Interpretation:
How Much Interpretation is Required?
How much residual uncertainty exists?

Unformed Figure, Jackson Pollock
American Gothic, Grant Wood
Expedited Programs

Why do we have expedited programs?

• To ensure therapies for serious conditions are developed efficiently and approved expeditiously
Expedited Programs

- Fast Track designation
- Breakthrough designation
- Priority Review designation
- Accelerated Approval
Expedited Programs

- Fast Track designation
- Breakthrough designation
- Priority Review designation
- Accelerated Approval
Fast Track Designation

Fast Track designation may be granted on the basis of preclinical or clinical data

Requirements:
1. Intended to treat a serious condition
2. Nonclinical or clinical data demonstrate the potential to address unmet medical need
Expedited Programs

- Fast Track designation
- Breakthrough designation
- Priority Review designation
- Accelerated Approval
Breakthrough Designation

Breakthrough designation may be granted on the basis of clinical data

Requirements:

1. Intended to treat a serious condition

2. Fill an unmet medical need

3. Preliminary clinical data to indicate that the drug may demonstrate substantial improvement over available therapy on one or more clinically significant endpoints
Breakthrough Designation

What does a breakthrough designation get you?

• Intensive guidance from FDA
• Organizational commitment
• Rolling review
Breakthrough (BT) Designations to Date*

**BT Requests Across CDER Office of New Drugs**

- **Hematology Oncology**
  - 208 (42%)
- **Other Offices**
  - 284 (58%)

N=492

36% granted across Office of New Drugs

**Office of Hematology & Oncology CDER**

- **Withdrawn**
  - 36 (17%)
- **Denied**
  - 71 (34%)
- **Granted**
  - 89 (43%)

* as of September 6, 2017
Drug or Biologics applications-review and approval pathways
Expedited Programs

- Fast Track designation
- Breakthrough designation
- Priority Review designation
- Accelerated Approval
Review Pathways

• Standard review

• Rolling review

• Priority review
  – NDA or BLA for a drug that treats a **serious condition**
  – If approved would provide a **significant improvement in safety or effectiveness**
  – 6 month vs 10 month review clock

• Expedited review
Expedited Programs

- Fast Track designation
- Breakthrough designation
- Priority Review designation
- Accelerated Approval
Approval Pathways

• Regular Approval: based on clinical benefit

• Accelerated Approval: based on effect on endpoint that is reasonably likely to predict clinical benefit (e.g., response rate in a single arm trial)
Accelerated Approval

- Benefits: smaller, quicker trials with earlier outcome data
- Risks: meaningful clinical benefit has not been confirmed yet
- 10% of accelerated approvals in oncology have been withdrawn for failure to confirm a benefit
A drug has received FDA Breakthrough Therapy Designation. Which statement is true?

a) The drug has shown promise based on results from animal studies
b) The drug has shown promise based on results from early clinical studies in humans
c) The drug has been approved for use on the U.S. market based on “breakthrough” results
A drug has received FDA Breakthrough Therapy Designation. Which statement is true?

a) The drug has shown promise based on results from animal studies
b) The drug has shown promise based on results from early clinical studies in humans
c) The drug has been approved for use on the U.S. market based on “breakthrough” results
A drug has been approved by FDA under the accelerated approval program.

Which statement is true?

a) The drug has shown an effect on overall survival in several large randomized trials
b) The drug has shown to have response rate similar to available therapy in a single-arm trial
c) The drug has shown to have a better response rate than available therapy in a single-arm trial
A drug has been approved by FDA under the accelerated approval program.
Which statement is true?

a) The drug has shown an effect on overall survival in several large randomized trials
b) The drug has shown to have response rate similar to available therapy in a single-arm trial
c) The drug has shown to have a better response rate than available therapy in a single-arm trial
FDA Drug Review vs. Label

Drug review
• Full review by each discipline
• Drugs@FDA

Drug label
• Agreed upon language between FDA and Sponsor
• Essential scientific information needed for the safe and effective use of the product
• Drugs@FDA, google, sponsor’s website, etc.
Acknowledgements

• Damiette Smit
• Leigh Marcus
• Paul Kluetz
• Julia Beaver